Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study
Iclaprim met the primary endpoint Iclaprim was well tolerated in the study Data from the second Phase 3 ABSSSI Trial, REVIVE-2, expected in the second half of 2017 NDA submission expected in the first half of 2018 Company to host conference call …